7 Analysts Assess Bio-Techne: What You Need To Know
Benzinga Insights 9 months ago
Analyst Ratings
In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 3 | 0 | 0 |
| Last 30D | 3 | 0 | 2 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Bio-Techne, presenting an average target of $71.71, a high estimate of $80.00, and a low estimate of $62.00. Observing a 7.95% increase, the current average has risen from the previous average price target of $66.43.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bio-Techne. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Donnelly | Citigroup | Raises | Buy | $80.00 | $70.00 |
| Daniel Arias | Stifel | Raises | Hold | $65.00 | $60.00 |
| Kyle Boucher | TD Cowen | Raises | Buy | $80.00 | $70.00 |
| Dan Leonard | UBS | Raises | Buy | $79.00 | $70.00 |
| Daniel Markowitz | Evercore ISI Group | Raises | In-Line | $68.00 | $62.00 |
| Daniel Markowitz | Evercore ISI Group | Lowers | In-Line | $62.00 | $68.00 |
| David Toung | Argus Research | Raises | Buy | $68.00 | $65.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bio-Techne. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bio-Techne compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Bio-Techne's stock. This examination reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Bio-Techne's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Bio-Techne analyst ratings.
Discovering Bio-Techne: A Closer Look
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
A Deep Dive into Bio-Techne's Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Bio-Techne's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -1.0% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.32%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bio-Techne's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.97%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Bio-Techne's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.2, Bio-Techne adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.